Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)
This study has been terminated.
(Most pts requested to be treated with versed. It was difficult to randomize pts.)
Sponsor:
Washington University School of Medicine
Collaborator:
Society of Pediatric Urology
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00894465
First received: May 4, 2009
Last updated: March 9, 2011
Last verified: March 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research is to validate the common administration of oral midazolam to children prior to voiding cystourethrogram (VCUG) to see if this will significantly decrease children's anxiety and make the experience less traumatic.
| Condition | Intervention |
|---|---|
|
Vesicoureteral Reflux |
Drug: midazolam Drug: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study Examining the Efficacy of Oral Midazolam in Reducing Anxiety in Children Undergoing Voiding Cystourethrogram |
Resource links provided by NLM:
Further study details as provided by Washington University School of Medicine:
Primary Outcome Measures:
- To determine the efficacy of oral midazolam in reducing anxiety in children undergoing VCUG test for VUR [ Time Frame: 1day, 7 days, 14 days and 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine if there is a difference in parents' perception of their child's anxiety during VCUG after pretreatment. [ Time Frame: 1 day, 7 days, 14 days and 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 44 |
| Study Start Date: | August 2006 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Versed
Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
|
Drug: midazolam
Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
|
|
Placebo Comparator: Placebo
Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
|
Drug: placebo
Children are randomized to receive a placebo prior to undergoing VCUG
|
Eligibility| Ages Eligible for Study: | 2 Years to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age 2-6 years
- Toilet trained
- English speaking
- Already scheduled for VCUG
Exclusion Criteria:
- Allergic to midazolam
- Active UTI
- Known urethral stricture
- Known urethral reconstruction
- Has history of abnormal sensation in pelvic area
- Has history of sexual abuse
- Has severe developmental delay
- Has diagnosis of anxiety disorders
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00894465
Locations
| United States, Missouri | |
| Washington University | |
| ST Louis, Missouri, United States, 63110 | |
Sponsors and Collaborators
Washington University School of Medicine
Society of Pediatric Urology
Investigators
| Principal Investigator: | Paul F Austin, MD | Washington University School of Medicine |
More Information
No publications provided
| Responsible Party: | Paul Austin, MD, Washington University |
| ClinicalTrials.gov Identifier: | NCT00894465 History of Changes |
| Other Study ID Numbers: | HRPO # 06-0665 |
| Study First Received: | May 4, 2009 |
| Last Updated: | March 9, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Washington University School of Medicine:
|
Midazolam VCUG Anxiety |
Additional relevant MeSH terms:
|
Vesico-Ureteral Reflux Urinary Bladder Diseases Urologic Diseases Midazolam Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants |
Physiological Effects of Drugs Psychotropic Drugs Hypnotics and Sedatives Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013